Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Kenny-Caffey syndrome, Type 1 × niraparib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 65 Breast Neoplasms 19 Fallopian Tube Neoplasms 17 Prostatic Neoplasms 15 Neoplasms 15 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Glioblastoma 7 Endometrial Neoplasms 6 Triple Negative Breast Neoplasms 5 Lung Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Mesothelioma 3 Melanoma 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Mesothelioma, Malignant 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

olaparib 1 niraparib 1 fluzoparib 1 Vernalization 1 Standard of Care 1 Poly(ADP-ribose) Polymerase Inhibitors 1 Irinotecan 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05044091 2021-09-14

HOPEI

Jiangsu Cancer Institute & Hospital

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡